Not a good buy right now for an impatient investor: options positioning is heavily bearish (puts dominate), insiders have been selling aggressively, and the statistical near-term pattern skews negative for the next week/month.
Technicals are bullish (trend up), but price is pressing into nearby resistance (~28.25) while RSI is elevated, so upside looks capped short-term unless a catalyst hits.
With earnings after-hours on 2026-02-11 (biotech binary risk) and no proprietary buy signals today, the risk/reward favors staying on the sidelines rather than buying immediately.
Technical Analysis
Trend/structure: Bullish alignment (SMA_5 > SMA_20 > SMA_200) indicates an established uptrend.
Momentum: MACD histogram is positive (0.027) but contracting → bullish momentum is weakening.
RSI (6): 68.46 (upper-neutral / near overbought) → less attractive for a fresh chase entry.
Key levels: Pivot 26.76. Immediate resistance R1 ~28.25 (current ~27.88 is close); next R2 ~29.17. Supports: S1 ~25.27, S2 ~24.35.
Short-term probability read: Pattern analog suggests +1.73% next day odds, but -10.19% next week and -6.91% next month → downside bias beyond the very near term.
Options Data
Bearish
Open Interest Put-Call Ratio
Bearish
Option Volume Put-Call Ratio
Positioning/sentiment: Open interest put/call ratio 4.6 and volume put/call ratio 5.0 → strongly bearish skew (traders hedging/speculating downside).
Open interest: Puts 2,378 vs calls 517 → downside protection demand dominates.
Volatility: 30D IV 78.74 vs historical vol 131.69; IV percentile 6.77 / IV rank 9.01 → implied vol is relatively low vs its own history (options not “priced for” extreme moves compared to prior periods).
Activity: Today’s option volume 6, about 2.16x 30-day average (still small absolute volume) → bearish skew stands out more than the raw volume size.
Technical Summary
Sell
2
Buy
11
Positive Catalysts
Pipeline catalyst potential: Company plans to advance ELVN-001 (leukemia) to Phase 3, which can be a meaningful valuation catalyst if execution/timelines are well-received.
Technical uptrend remains intact as long as price holds above the ~26.76 pivot area.
Low IV percentile/rank could make upside re-pricing possible if news surprises positively (though positioning is currently bearish).
Neutral/Negative Catalysts
→ near-term event risk.
Financial Performance
Latest reported quarter: 2025/Q3.
Revenue: 0 (no YoY change) → pre-revenue profile consistent with clinical-stage biotech.
Profitability: Net income -$20.15M (worse YoY by ~12.99%); EPS -0.32 (worse YoY by ~33.33%) → losses expanding.
Overall: Financial trend reflects continued cash burn without revenue offset; near-term stock performance is likely to be driven more by clinical/strategic milestones than fundamentals.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
No analyst rating or price target change data was provided, so a specific recent trend in upgrades/downgrades cannot be confirmed.
Wall Street-style “pros” view (typical for this setup): Phase-advancement potential (ELVN-001 to Phase 3) can meaningfully improve probability-weighted value if data/timelines remain strong.
Wall Street-style “cons” view: Pre-revenue with widening losses, heavy dependence on clinical milestones, and insider selling/put-heavy options positioning point to cautious near-term sentiment.
Wall Street analysts forecast ELVN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ELVN is 40.2 USD with a low forecast of 35 USD and a high forecast of 48 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Analyst Rating
Wall Street analysts forecast ELVN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ELVN is 40.2 USD with a low forecast of 35 USD and a high forecast of 48 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 26.990
Low
35
Averages
40.2
High
48
Current: 26.990
Low
35
Averages
40.2
High
48
H.C. Wainwright
H.C. Wainwright
NULL -> Buy
maintain
$40 -> $48
AI Analysis
2025-07-02
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$40 -> $48
AI Analysis
2025-07-02
maintain
NULL -> Buy
Reason
H.C. Wainwright raised the firm's price target on Enliven to $48 from $40 and keeps a Buy rating on the shares after the company presented updated results from the Phase 1a/1b ENABLE trial at EHA 2025. Following the presentation at the medical meeting, the firm contends that ELVN-001 could become "the go-to agent" in chronic myelogenous leukemia.
Goldman Sachs
Salveen Richter
NULL -> Buy
upgrade
$37
2025-06-17
Reason
Goldman Sachs
Salveen Richter
Price Target
$37
2025-06-17
upgrade
NULL -> Buy
Reason
Goldman Sachs analyst Salveen Richter assigned of Enliven with a Buy rating and $37 price target from a previous Early-Stage Biotech designation. The firm cites the company's continued positive Phase 1 data and the announcement of a planned Phase 3 initiation in 2026 for tyrosine kinase inhibitor ELVN-001 in chronic myeloid leukemia for the Buy rating. ELVN-001 remains well-tolerated, with no increased cardiovascular toxicity, and the data supports the potential for once daily dosing without the need for fasting and low drug-drug interactions, the analyst tells investors in a research note.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for ELVN
